Shaun Shurtliff, DO
Family Medicine · Vernal, UTNPI 1285719294
Payments from drug & device makers
Across 375 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Pfizer$566
- Novo Nordisk$487
- Lilly USA, LLC$328
- Johnson & Johnson$269
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,63499%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,097 |
| AbbVie(2 entities) | 57 | $1,060 |
| Pfizer | 67 | $566 |
| Novo Nordisk | 46 | $487 |
| Lilly USA, LLC | 23 | $328 |
| Johnson & Johnson(2 entities) | 18 | $269 |
| Novartis | 14 | $263 |
| Boehringer Ingelheim | 10 | $192 |
| Corcept Therapeutics | 7 | $154 |
| Xeris Pharmaceuticals, Inc. | 8 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $136 |
| Bayer | 6 | $125 |
| Astellas Pharma US Inc | 5 | $104 |
| E.r. Squibb & Sons, L.L.C. | 6 | $94 |
| Merck | 6 | $83 |
| GSK | 5 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $53 |
| Linus Health, Inc. | 1 | $52 |
| Abbott | 3 | $50 |
| Organon | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $29 |
| Adlon Therapeutics L.p. | 2 | $29 |
| Amgen(2 entities) | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Scynexis, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Pharmaessentia USA Corporation | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Ardelyx, Inc. | 1 | $14 |
| Vertex | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$5,678 in reported general payments places this provider in the 80th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 165 | $188,186 |
| OzempicSemaglutide | 163 | $176,208 |
| EliquisApixaban | 212 | $145,160 |
| JardianceEmpagliflozin | 153 | $130,319 |
| FarxigaDapagliflozin Propanediol | 85 | $63,411 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $54,688 |
| TrulicityDulaglutide | 54 | $53,119 |
| XareltoRivaroxaban | 59 | $42,432 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $31,037 |
| LinzessLinaclotide | 57 | $31,011 |
| VraylarCariprazine Hcl | 18 | $27,553 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $26,118 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $24,500 |
| Nurtec OdtRimegepant Sulfate | 15 | $24,202 |
| MovantikNaloxegol Oxalate | 48 | $23,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $328 | $241,305219 claims |
| Novo NordiskOzempic | $487 | $176,208163 claims |
| PfizerEliquis, Nurtec Odt | $566 | $169,362227 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Synjardy Xr | $192 | $162,661216 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,097 | $118,099158 claims |
| AbbVieLinzess, Vraylar, Viberzi | $1,060 | $78,10088 claims |
| Johnson & JohnsonXarelto | $269 | $42,43259 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $67 | $42,04362 claims |
| Astellas Pharma US IncMyrbetriq | $104 | $18,91636 claims |
| MerckJanuvia | $83 | $18,06718 claims |
| NovartisEntresto | $263 | $14,89722 claims |
| BayerKerendia | $125 | $7,78012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 928 family medicine providers in Utah.
Other family medicine in Vernal
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
- Sarang YoonSalt Lake City$9.4M
- Michael AdamsSandy$8.1M
- Katie JulienSouth Jordan$7.1M
- Scott EricksonBountiful$3.7M
- John RichardsSouth Jordan$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.